Every Form 4 that Revelation Biosciences, Inc. Warrant (REVBW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow REVBW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REVBW filings page.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
REVELATION BIOSCIENCES, INC. (REVB) reported that director Lakhmir S. Chawla acquired 32,011 shares of common stock on August 17, 2026 via a restricted stock award granted at $0.00 per share under the company’s 2021 Equity Incentive Plan. Following this grant, Chawla holds 44,169 shares directly. The award vests 50% on the two-year anniversary and 50% on the four-year anniversary of the grant date, subject to continued service, with potential acceleration upon certain performance milestones.
REVELATION BIOSCIENCES, INC. (REVB) reported that its Chief Financial Officer, Chester S. Zygmont III, received a restricted stock award of 208,073 shares of Common Stock under the company’s 2021 Equity Incentive Plan. The award vests with 50% on the two-year anniversary of the grant date and the remaining 50% on the four-year anniversary, subject to continued service and possible acceleration upon performance milestones. On the same date, Zygmont made a bona fide gift of 208,073 shares to The Zygmont Family Trust, which now holds 300,136 shares indirectly, and an affiliated LLC holds an additional 2 shares indirectly.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
REVELATION BIOSCIENCES, INC. (symbol: REVB) is the issuer of record for a Form 4 filing submitted to the SEC.
Revelation Biosciences, Inc. CEO James Rolke reported a mandatory tax-related share disposition. On the vesting of restricted stock awards, the issuer sold 10,115 shares of common stock on his behalf solely to cover required tax withholding obligations.
The weighted average sale price was $1.13 per share, with individual trades between $1.12 and $1.14. After this tax-withholding transaction, Rolke directly holds 214,738 shares of common stock. The footnotes state he did not exercise investment discretion over these sales.
Revelation Biosciences Chief Financial Officer reports a routine tax-related share sale through a trust. On the reported date, 13,285 shares of common stock were disposed of at a weighted average price of $1.10 per share to satisfy required tax withholding on vested restricted stock awards. The filing states this transaction was mandatory and that the CFO did not exercise investment discretion. After this tax-withholding disposition, an indirect trust holding stands at 92,063 shares of common stock, and an affiliated LLC holds 2 additional common shares indirectly.
Revelation Biosciences director Jess Roper reported a mandatory tax-related share sale. On February 3, 2026, the issuer sold 1,591 shares of common stock on Roper’s behalf to cover tax obligations arising from vested restricted stock awards. The weighted average sale price was $1.85 per share, with individual trades ranging from $1.84 to $1.88. After this transaction, Roper directly beneficially owned 12,828 common shares. All share amounts reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
Revelation Biosciences director Lakhmir S. Chawla had 2,261 common shares sold on February 3, 2026 to cover taxes on vesting restricted stock. The issuer sold the shares on the director’s behalf at a weighted average price of $1.85 per share.
After this mandatory tax-withholding transaction, Chawla beneficially owned 12,158 common shares directly. All share figures reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.
Revelation Biosciences, Inc. Chief Financial Officer Chester S. Zygmont III reported a mandatory sale of 13,100 shares of common stock on February 4, 2026. The issuer sold these shares on his behalf solely to cover tax withholding from vesting restricted stock awards.
The weighted average sale price was $1.65 per share, with individual trades ranging from $1.63 to $1.66. All share figures reflect a 1-for-4 reverse stock split effective January 28, 2026. After the transaction, 105,348 shares are held indirectly by The Zygmont Family Trust and 2 shares are held indirectly by Czeslaw Capital Fund, LLC, both entities associated with the CFO.